Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TomaGold Borehole EM Survey Confirms Berrigan Deep Zone (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Natera Inc NTRA

Healthcare Diagnostics & Research
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single... see more

Recent & Breaking News (NDAQ:NTRA)

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Business Wire 18 hours ago

Natera Submits Signatera(TM) CDx PMA to FDA

Business Wire 4 days ago

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

Business Wire 9 days ago

Prospera(TM) Featured in Landmark Interventional Study Advancing Lung Transplant Care

Business Wire 11 days ago

Natera Publishes Clinical Validation of Latitude(TM) Tissue-Free MRD Test in Colorectal Cancer

Business Wire January 21, 2026

Natera's Fetal Focus(TM) Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

Business Wire January 20, 2026

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

Business Wire January 13, 2026

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

Business Wire January 12, 2026

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera(TM) Growth

Business Wire January 11, 2026

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

Business Wire January 7, 2026

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

Business Wire January 5, 2026

Natera Launches 21-Gene Fetal Focus(TM) Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP(TM) Technology

Business Wire January 5, 2026

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Business Wire December 22, 2025

Natera Announces Publication of Signatera(TM) Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

Business Wire December 18, 2025

I-SPY 2 Publication in Nature Communications Shows Signatera(TM) Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

Business Wire December 16, 2025

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

Business Wire December 12, 2025

Phase III PALLAS Study Shows Signatera(TM) MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

Business Wire December 10, 2025

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

Business Wire December 9, 2025

Natera Acquires Foresight Diagnostics

Business Wire December 5, 2025

New Signatera(TM) Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

Business Wire December 3, 2025

Podcasts